Bristol-Myers Squibb Company (BMY) Valuation & Financial Model
Interactive Discounted Cash Flow (DCF) model for Bristol-Myers Squibb Company (US:BMY), trading at 64.86. In 2025, Bristol-Myers Squibb Company generated $48.19 Billion in revenue and $12.85 Billion in free cash flow. Explore projected intrinsic value assumptions based on institutional-grade macro metrics.
Valuation Methodology & Recent Performance
The financial model for Bristol-Myers Squibb Company is calculated using an institutional discounted cash flow (DCF) engine utilizing recent operational metrics:
- Current Price: 64.86
- Recent Revenue (2025): $48.19 Billion
- Free Cash Flow (2025): $12.85 Billion
- Discount Rate (WACC): Derived using the Risk-Free Rate (e.g., 10Y Gov Bond) plus an Equity Risk Premium based on market volatility and stock price variance.
- Terminal Value: Projected using a perpetual growth model bounded by long-term macroeconomic estimates.